Corporate Information – Page 18 – Alligator Bioscience

2023-04-12

Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in Q1 2024

OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer Inte ...

2023-04-03

Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma

OPTIMIZE-2 is a Phase 2 study to assess the safety and efficacy of mitazalimab in combination with a PD-1 inhibitor in patients affected by ...

2023-03-22

Notice of extraordinary general meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 24 ...

2023-03-14

Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer

Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE ...

2023-03-10

Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB

Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employ ...

2023-02-14

Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB

Laura von Schantz, employee representative, has resigned from the Alligator Bioscience AB Board of Directors, effective February 14, 2023, f ...

2023-02-13

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 Lund, Sweden, and Seattle, Washington, February ...

2023-02-13

Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology O ...

2023-01-09

Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...